bioMérieux S.A.. (2/28/18). "Press Release: 2017 Financial Results".

	Organisation	bioMérieux S.A. (Euronext: BIM)
	Group	Mérieux (Group)
	Organisation 2	Banyan Biomarkers Inc.
	Product	in vitro diagnostics (IVD)
	Product 2	molecular diagnostics
	Index term	Qvella–Mérieux: investment, 201712 financing round Series B totalling $20m incl co-lead + new strategic investor bioMérieux
	Person	Mérieux, Alexandre (Mérieux 201712– CEO at bioMérieux before Deputy CEO before VP Industrial Microbiology)

>Excellent sales momentum in 2017 with a 10.2% increase in sales, at constant exchange rates and scope of consolidation:
–– €2,288 million in sales
–– Up 8.8% as reported

> Strong 12.4% increase in contributive operating income before non-recurring items to €335 million, in line with the objectives set

> Fast growth in free cash flow to €164 million versus €85 million in 2016

> 2018 objectives:
–– Organic growth in sales of between 8% and 9%, at constant exchange rates and scope of consolidation
–– Contributive operating income before non-recurring items of between €325 million and €345 million, despite a negative currency impact anticipated at around €40 million

Alexandre Mérieux, Chairman and Chief Executive Officer, said: “bioMérieux delivered another solid operating and financial performance in 2017. Thanks to a robust sales momentum and careful control of operating expenses, the Company recorded sharp increases in contributive operating income before non-recurring items, net income and free cash flow. Buoyed by these results, we head into 2018 with the ambition to sustain this dynamic while strengthening our commitment to innovation and R&D.”

Download [Full release at http://www.biomerieux.com/sites/corporate/files/news-event-press-release/biomerieux_pr_2017_results.pdf ]

Record changed: 2023-06-05